Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

被引：0

作者：

Dickinson, Michael ^{[1
,2
]}

Carlo-Stella, Carmelo ^{[3
,4
]}

Morschhauser, Franck ^{[5
,6
]}

Bachy, Emmanuel ^{[7
]}

Corradini, Paolo ^{[8
,9
]}

Iacoboni, Gloria ^{[10
]}

Khan, Cyrus ^{[11
]}

Wrobel, Thomasz ^{[12
]}

Offner, Fritz ^{[13
]}

Trneny, Marek ^{[14
]}

Wu, Shang-Ju ^{[15
]}

Cartron, Guillaume ^{[16
]}

Hertzberg, Mark ^{[17
,18
]}

Sureda, Anna ^{[19
]}

Perez-Callejo, David ^{[20
]}

Lundberg, Linda ^{[20
]}

Relf, James ^{[21
]}

Clark, Emma ^{[21
]}

Humphrey, Kathryn ^{[21
]}

Hutchings, Martin ^{[22
]}

机构：

[1] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Melbourne, Vic, Australia

[3] Humanitas Univ, Milan, Italy

[4] IRCCS Humanitas Res Hosp, Milan, Italy

[5] Hop Claude Huriez, Lille, France

[6] CHU Lille, Lille, France

[7] Ctr Hosp Lyon Sud, Lyon, France

[8] Univ Milan, Milan, Italy

[9] IRCSS Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy

[10] Vall dHebron Univ Hosp, Barcelona, Spain

[11] Allegheny Hlth Network, Pittsburgh, PA USA

[12] Uniwersytet Med Wroclawiu, Wroclaw, Poland

[13] Univ Ziekenhuis Gent, Ghent, Belgium

[14] Charles Univ Hosp, Prague, Czech Republic

[15] Natl Taiwan Univ Hosp, Taipei, Taiwan

[16] CHU Montpellier, Montpellier, France

[17] Prince Wales Hosp, Sydney, NSW, Australia

[18] Univ New South Wales, Sydney, NSW, Australia

[19] Inst Catala Oncol Hosp, Barcelona, Spain

[20] F Hoffmann La Roche Ltd, Basel, Switzerland

[21] Roche Prod Ltd, Welwyn Garden City, Herts, England

[22] Rigshosp, Copenhagen, Denmark

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

ABCL; glofitamab; diffuse large B-cell lymphoma; bispecific antibody; relapsed/refractory; phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-478

引用

页码：S435 / S435

页数：1

共 50 条

[21] Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data
Ferhanoglu, Burhan
Gulbas, Zafer
Uzay, Ant
Ozcan, Muhit
Ozkalemkas, Fahir
Dal, Mehmet Sinan
Kalyon, Hakan
Akay, Olga Meltem
Deveci, Burak
Bekoz, Huseyin
Sevindik, Omur Gokmen
Toptas, Tayfur
Yilmaz, Asu Fergun
Koyun, Derya
Alkis, Nihan
Atesoglu, Elif Birtas
BLOOD, 2022, 140 : 6704 - 6705
[22] A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Crombie, Jennifer L.
Kim, Austin I.
Bartlett, Nancy L.
Redd, Robert A.
Patterson, Victoria
Carey, Celeste
Balasubramanian, Sobana
Odejide, Oreofe O.
Merryman, Reid W.
LaCasce, Ann
Jacobson, Caron A.
Jacobsen, Eric
Parry, Erin M.
Fisher, David C.
Herrera, Alex F.
Davids, Matthew S.
Shipp, Margaret A.
Armand, Philippe
Shouse, Geoffrey P.
BLOOD, 2023, 142
[23] New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma
Moore, Donald C.
Peery, Matthew R.
Tobon, Katherine A.
Raheem, Farah
Hwang, Grace S.
Alhennawi, Lin
Hughes, Mitchell E.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1848 - 1858
[24] Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies
Sawalha, Yazeed
JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (12):
[25] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Ren, Liangliang
Li, Ling
Zhang, Lei
Li, Xin
Fu, Xiaorui
Wang, Xinhua
Wu, Jingjing
Sun, Zhenchang
Feng, Xiaoyan
Chang, Yu
Zhou, Zhiyuan
Nan, Feifei
Yan, Jiaqin
Kong, Fei
Zhang, Mingzhi
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (01) : 42 - 50
[26] Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
Palomba, M. Lia
Till, Brian G.
Park, Steven I.
Morschhauser, Franck
Cartron, Guillaume
Marks, Reinhard
Shivhare, Mahesh
Hong, Wan-Jen
Raval, Aparna
Chang, Alice C.
Penuel, Elicia
Popplewell, Leslie L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E443 - E451
[27] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Liangliang Ren
Ling Li
Lei Zhang
Xin Li
Xiaorui Fu
Xinhua Wang
Jingjing Wu
Zhenchang Sun
Xiaoyan Feng
Yu Chang
Zhiyuan Zhou
Feifei Nan
Jiaqin Yan
Fei Kong
Mingzhi Zhang
Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 42 - 50
[28] Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase II Study
Bennani, N. Nora
Atherton, Pamela
Steinert, Kimberly O.
Rimsza, Lisa M.
Tun, Aung M.
Hoffmann, Marc S.
Narkhede, Mayur S.
Vaidya, Rakhee
Said, Rabih
Shapiro, Geoffrey I.
Costello, Brian A.
Ansell, Stephen M.
Nowakowski, Grzegorz S.
BLOOD, 2023, 142
[29] Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study
Falchi, Lorenzo
Carlo-Stella, Carmelo
Morschhauser, Franck
Hutchings, Martin
Bachy, Emmanuel
Cartron, Guillaume
Khan, Cyrus
Tani, Monica
Martinez-Lopez, Joaquin
Bartlett, Nancy L.
Salar, Antonio
Brody, Joshua
Leppa, Sirpa
Mulvihill, Estafania
Lundberg, Linda
Relf, James
Xie, Yuying
Bottos, Alessia
Humphrey, Kathryn
Dickinson, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30] Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Lenz, Georg
Hawkes, Eliza
Verhoef, Gregor
Haioun, Corinne
Thye, Lim Soon
Heo, Dae Seog
Ardeshna, Kirit
Chong, Geoffrey
Christensen, Jacob Haaber
Shi, Vivian
Lippert, Susanne
Niemeyer, Florian
Piraino, Paolo
Pena, Carol Elaine
Buvaylo, Viktoriya
Childs, Barrett H.
Gorbatchevsky, Igor
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →